About Chimerix (NASDAQ:CMRX)
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074
Debt
Debt-to-Equity RatioN/A
Current Ratio11.87%
Quick Ratio11.87%
Price-To-Earnings
Trailing P/E Ratio-3.36
Forward P/E Ratio-2.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.49 million
Price / Sales53.81
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book1.08
Profitability
EPS (Most Recent Fiscal Year)($1.51)
Net Income$-70,980,000.00
Net Margins-1,579.53%
Return on Equity-29.22%
Return on Assets-28.07%
Miscellaneous
Employees82
Outstanding Shares47,650,000
Chimerix (NASDAQ:CMRX) Frequently Asked Questions
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix Inc. (NASDAQ:CMRX) issued its earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.07. The biopharmaceutical company had revenue of $1.84 million for the quarter, compared to analysts' expectations of $0.83 million. Chimerix had a negative net margin of 1,579.53% and a negative return on equity of 29.22%. View Chimerix's Earnings History.
When is Chimerix's next earnings date?
What price target have analysts set for CMRX?
4 equities research analysts have issued 12 month target prices for Chimerix's shares. Their forecasts range from $6.00 to $10.00. On average, they expect Chimerix's stock price to reach $7.6667 in the next twelve months. View Analyst Ratings for Chimerix.
What are Wall Street analysts saying about Chimerix stock?
Here are some recent quotes from research analysts about Chimerix stock:
- 1. HC Wainwright analysts commented, "Data from AdVance Make Us More Confident in the Potential Success of AdAPT; Reiterate Buy Strong correlation between mortality and adenovirus (AdV) burden. This morning, Chimerix announced data from the AdVance study, which was conducted to investigate AdV incidence, natural history, management and clinical outcomes in allogeneic hematopoietic cell transplant (allo-HCT) recipients. This large multi-center study, which was conducted in 2017, examined the incidence, practice patterns, hospitalization and clinical outcomes of 4,276 allo-HCT recipients, which included 1,738 pediatric patients and 2,538 adults. Results among the pediatric allo-HCT patients in the study demonstrated that highest mortality was observed in recipients with the greatest AdV burden, with 52% mortality in the patient quartile with highest time-averaged area under the curve (AAUC) compared to 3% mortality reported in the patient quartile with lowest AAUC." (3/19/2018)
- 2. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (3/6/2018)
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include Innate Pharma (IPHYF), MediciNova (MNOV), Zealand Pharma (ZEAL), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corium International (CORI), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP) and GTX (GTXI).
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- Dr. M. Michelle Berrey, Pres, CEO & Director (Age 51)
- Mr. Timothy W. Trost, Sr. VP, CFO, Principal Accounting Officer & Corp. Sec. (Age 60)
- Ms. Linda M. Richardson, Chief Strategy & Commercial Officer (Age 54)
- Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 49)
- Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
Has Chimerix been receiving favorable news coverage?
News coverage about CMRX stock has been trending somewhat positive this week, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Chimerix earned a media sentiment score of 0.16 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 47.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Chimerix?
Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of CMRX stock can currently be purchased for approximately $5.07.
How big of a company is Chimerix?
Chimerix has a market capitalization of $241.60 million and generates $4.49 million in revenue each year. The biopharmaceutical company earns $-70,980,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Chimerix employs 82 workers across the globe.
How can I contact Chimerix?
Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]
MarketBeat Community Rating for Chimerix (CMRX)
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Chimerix (NASDAQ:CMRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Chimerix in the last 12 months. Their average twelve-month price target is $7.6667, suggesting that the stock has a possible upside of 51.22%. The high price target for CMRX is $10.00 and the low price target for CMRX is $6.00. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.6667 | $7.6667 | $6.50 | $6.50 |
| Price Target Upside: | 51.22% upside | 35.93% upside | 9.70% upside | 9.70% upside |
Chimerix (NASDAQ:CMRX) Consensus Price Target History
Chimerix (NASDAQ:CMRX) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Chimerix (NASDAQ:CMRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Chimerix (NASDAQ CMRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.50%
Institutional Ownership Percentage: 74.39%
Chimerix (NASDAQ CMRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/1/2017 | Linda M Richardson | Insider | Sell | 19,833 | $4.47 | $88,653.51 | |  |
| 12/28/2016 | Ernest Mario | Director | Sell | 100,000 | $4.64 | $464,000.00 | 12,905 | |
| 9/15/2016 | John M Leonard | Director | Sell | 5,000 | $5.03 | $25,150.00 | | |
| 8/29/2016 | M Michelle Berrey | Insider | Buy | 22,417 | $4.47 | $100,203.99 | 281,238 | |
| 6/24/2016 | Ernest Mario | Director | Buy | 50,000 | $3.70 | $185,000.00 | 381,440 | |
| 6/24/2016 | M Michelle Berrey | CEO | Buy | 13,188 | $3.69 | $48,663.72 | 258,821 | |
| 5/13/2016 | Ernest Mario | Director | Buy | 10,000 | $4.53 | $45,300.00 | 331,440 | |
| 5/11/2016 | Ernest Mario | Director | Buy | 25,000 | $4.85 | $121,250.00 | 297,240 | |
| 5/10/2016 | Ernest Mario | Director | Buy | 800 | $4.76 | $3,808.00 | 297,240 | |
| 3/16/2016 | Ernest Mario | Director | Buy | 25,000 | $5.06 | $126,500.00 | 287,919 | |
| 3/15/2016 | Ernest Mario | Director | Buy | 20,000 | $5.13 | $102,600.00 | 287,919 | |
| 3/1/2016 | Martha J Demski | Director | Buy | 10,000 | $4.89 | $48,900.00 | 10,000 | |
| 12/29/2015 | Ernest Mario | Director | Buy | 125,000 | $7.09 | $886,250.00 | 262,637 | |
| 11/2/2015 | Martha J. Demski | Director | Sell | 1,126 | $41.35 | $46,560.10 | | |
| 10/1/2015 | Martha J. Demski | Director | Sell | 2,000 | $37.68 | $75,360.00 | | |
| 9/1/2015 | Martha J. Demski | Director | Sell | 2,000 | $48.18 | $96,360.00 | | |
| 8/21/2015 | John M Leonard | Director | Buy | 1,000 | $47.38 | $47,380.00 | 4,000 | |
| 7/17/2015 | Timothy W Trost | CFO | Sell | 28,000 | $50.00 | $1,400,000.00 | | |
| 7/1/2015 | Martha J Demski | Director | Sell | 2,000 | $46.03 | $92,060.00 | | |
| 6/1/2015 | Martha J Demski | Director | Sell | 2,000 | $41.58 | $83,160.00 | | |
| 5/1/2015 | Martha J Demski | Director | Sell | 2,000 | $34.71 | $69,420.00 | | |
| 3/2/2015 | Martha J Demski | Director | Sell | 2,000 | $40.18 | $80,360.00 | | |
| 2/2/2015 | Martha J Demski | Director | Sell | 2,000 | $38.38 | $76,760.00 | | |
| 1/2/2015 | Martha J Demski | Director | Sell | 2,000 | $41.08 | $82,160.00 | | |
| 11/5/2014 | John M Leonard | Director | Buy | 4,000 | $29.00 | $116,000.00 | | |
| 9/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $27.75 | $138,750.00 | | |
| 9/11/2014 | James Niedel | Director | Sell | 1,099,949 | $29.39 | $32,327,501.11 | | |
| 9/9/2014 | Sanderling Venture Partners V, | Major Shareholder | Sell | 122,950 | $29.28 | $3,599,976.00 | | |
| 9/8/2014 | Timothy Wollaeger | Director | Sell | 100,000 | $24.54 | $2,454,000.00 | | |
| 9/5/2014 | Ernest Mario | Director | Buy | 10,000 | $23.19 | $231,900.00 | | |
| 8/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $25.13 | $125,650.00 | | |
| 7/25/2014 | Timothy W Trost | Insider | Sell | 5,000 | $22.35 | $111,750.00 | | |
| 6/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $22.74 | $113,700.00 | | |
| 5/27/2014 | Ernest Mario | Director | Buy | 10,000 | $14.22 | $142,200.00 | | |
| 5/27/2014 | M Michelle Berrey | Insider | Buy | 14,065 | $14.22 | $200,004.30 | | |
| 5/27/2014 | Timothy W Trost | CFO | Sell | 5,000 | $17.41 | $87,050.00 | | |
| 4/25/2014 | Timothy W Trost | Insider | Sell | 5,000 | $18.67 | $93,350.00 | | |
| 3/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $25.37 | $126,850.00 | | |
| 2/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $19.29 | $96,450.00 | | |
| 1/27/2014 | Timothy W Trost | CFO | Sell | 5,000 | $18.26 | $91,300.00 | | |
| 12/26/2013 | Timothy W Trost | CFO | Sell | 5,000 | $15.21 | $76,050.00 | | |
| 12/13/2013 | Ernest Mario | Director | Buy | 5,000 | $13.90 | $69,500.00 | | |
| 12/9/2013 | Rodman L Drake | Director | Buy | 1,000 | $14.35 | $14,350.00 | | |
| 11/25/2013 | Ernest Mario | Director | Buy | 8,000 | $15.20 | $121,600.00 | | |
| 11/19/2013 | Ernest Mario | Director | Buy | 7,500 | $15.25 | $114,375.00 | | |
| 11/15/2013 | Rodman L Drake | Director | Buy | 1,000 | $15.56 | $15,560.00 | | |
| 10/25/2013 | Timothy W Trost | CFO | Sell | 5,000 | $16.04 | $80,200.00 | | |
| 10/23/2013 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 585,602 | $15.51 | $9,082,687.02 | | |
| 10/23/2013 | Vii L P Canaan | Director | Sell | 674,771 | $15.51 | $10,465,698.21 | | |
| 8/30/2013 | Ernest Mario | Director | Buy | 5,064 | $15.82 | $80,112.48 | | |
| 8/26/2013 | Ernest Mario | Director | Buy | 5,960 | $17.20 | $102,512.00 | | |
| 8/23/2013 | M Michelle Berrey | Insider | Buy | 5,540 | $18.70 | $103,598.00 | | |
| 8/20/2013 | Ernest Mario | Director | Buy | 4,040 | $17.48 | $70,619.20 | | |
(Data available from 1/1/2013 forward)
Chimerix (NASDAQ CMRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect Chimerix Inc. (CMRX) Will Announce Quarterly Sales of $1.12 Million
www.americanbankingnews.com - April 13 at 2:52 AM |
| Brokerages Anticipate Chimerix Inc. (CMRX) to Post -$0.43 Earnings Per Share
www.americanbankingnews.com - April 11 at 1:12 PM |
| Chimerix (CMRX) Downgraded by ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM |
 | Chimerix (CMRX) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 4:33 PM |
| Chimerix Inc. (CMRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 5 at 11:15 AM |
 | Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 2 at 4:34 PM |
 | Chimerix to Present at the HC Wainwright Annual Global Life Sciences Conference
globenewswire.com - April 2 at 9:52 AM |
 | Look what Triangle woman just became chairwoman of a $250M company
www.bizjournals.com - March 30 at 4:33 PM |
 | BRIEF-Chimerix Announces Martha J. Demski As Board Chair
www.reuters.com - March 30 at 9:30 AM |
| Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors
finance.yahoo.com - March 30 at 9:30 AM |
| $1.12 Million in Sales Expected for Chimerix Inc. (CMRX) This Quarter
www.americanbankingnews.com - March 27 at 4:00 AM |
| Analysts Anticipate Chimerix Inc (CMRX) to Post -$0.43 Earnings Per Share
www.americanbankingnews.com - March 25 at 1:16 PM |
| Durham pharma pushing to fight a common cold virus that's deadly to some patients
www.bizjournals.com - March 24 at 4:26 PM |
| Durham pharma pushing to fight a common cold virus that's deadly to some patients
finance.yahoo.com - March 23 at 9:23 AM |
| European, multi-center study reinforces need for effective therapies for adenovirus in immunocompromised patients
globenewswire.com - March 20 at 9:36 AM |
| Chimerix (CMRX) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 19 at 12:00 PM |
| The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk
finance.yahoo.com - March 19 at 9:35 AM |
| Chimerix (CMRX) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 17 at 6:44 PM |
| Chimerix Inc (CMRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 11 at 9:48 AM |
| Chimerix (CMRX) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 10 at 6:34 PM |
| -$0.43 EPS Expected for Chimerix Inc (CMRX) This Quarter
www.americanbankingnews.com - March 8 at 1:56 PM |
| Chimerix to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 9:30 AM |
| Chimerix (CMRX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 6 at 8:36 PM |
 | Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
www.zacks.com - March 6 at 9:15 AM |
| Prosight Management LP Takes $6.85 Million Position in Chimerix Inc (CMRX)
www.americanbankingnews.com - March 5 at 4:06 PM |
| Chimerix (CMRX) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - March 2 at 10:39 AM |
| Ascend Capital LLC Purchases 344,311 Shares of Chimerix Inc (CMRX)
www.americanbankingnews.com - March 2 at 4:32 AM |
| Cowen Reiterates Hold Rating for Chimerix (CMRX)
www.americanbankingnews.com - March 1 at 5:40 PM |
| Chimerix Inc (CMRX) Shares Bought by Victory Capital Management Inc.
www.americanbankingnews.com - February 26 at 5:54 AM |
| Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
finance.yahoo.com - February 22 at 9:14 AM |
| Analysts Anticipate Chimerix Inc (CMRX) Will Announce Quarterly Sales of $830,000.00
www.americanbankingnews.com - February 21 at 6:54 AM |
| Chimerix (CMRX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:22 AM |
| Chimerix (CMRX) Lowered to "Underweight" at JPMorgan Chase & Co.
www.americanbankingnews.com - February 14 at 10:40 PM |
| Chimerix Inc (CMRX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 14 at 11:06 AM |
| Chimerix Inc (CMRX) Expected to Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - February 4 at 4:54 AM |
| HC Wainwright Begins Coverage on Chimerix (CMRX)
www.americanbankingnews.com - February 3 at 2:52 PM |
| Chimerix Inc (CMRX) Expected to Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - February 2 at 3:28 PM |
| Chimerix (CMRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 22 at 9:18 PM |
| Zacks: Analysts Anticipate Chimerix Inc (CMRX) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 18 at 4:38 AM |
| -$0.49 Earnings Per Share Expected for Chimerix Inc (CMRX) This Quarter
www.americanbankingnews.com - January 16 at 5:08 PM |
| Chimerix (CMRX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 7:12 PM |
| Wired News – Chimerix Announced Initiation of AdAPT Study for Oral Brincidofovir and Advancement of IV Brincidofovir to Phase-2 Studies
finance.yahoo.com - January 8 at 10:05 AM |
| BRIEF-Chimerix Initiates Adapt Study For Oral Brincidofovir
www.reuters.com - January 5 at 4:48 PM |
| Recent Analysis Shows Chimerix, Highwoods Properties, HubSpot, Biglari, IDEXX Laboratories, and Argan Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - January 5 at 9:56 AM |
| Chimerix Initiates AdAPT Study for Oral Brincidofovir and Advances IV Brincidofovir to Patient Studies
finance.yahoo.com - January 5 at 9:56 AM |
| Chimerix to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:06 PM |
| Chimerix Inc (CMRX) Short Interest Update
www.americanbankingnews.com - January 1 at 3:07 AM |
| Chimerix Inc (CMRX) Expected to Announce Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 1 at 3:00 AM |
| Brokerages Anticipate Chimerix Inc (CMRX) Will Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - December 30 at 9:14 PM |
| Head-To-Head Comparison: GlycoMimetics (GLYC) versus Chimerix (CMRX)
www.americanbankingnews.com - December 30 at 1:18 PM |
Chimerix (NASDAQ:CMRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Chimerix (NASDAQ:CMRX) Income Statement, Balance Sheet and Cash Flow Statement
Chimerix (NASDAQ CMRX) Stock Chart for Sunday, April, 22, 2018
Loading chart…
